Source study found

Story checked

Private equity hospice buyouts drive up Medicare spending (opens in a new tab)

news-medical.net · 2026-11-03

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

2 supported
3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Private equity hospice buyouts drive up Medicare spending

news-medical.net · 2026-11-03

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

Every claim we could check holds up. Two of five claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

2 supported
3 not covered

Open claim evidence

The source study

Changes In Hospice Use, Medicare Spending, And Patient Outcomes After Private Equity Acquisition

Health Affairs (Project Hope) · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe increase in spending was driven mainly by longer stays, with the average length of stay rising by 6.3 days.View evidenceHide evidence

As stated6.3 days

Why this verdict

The +6.3-day increase in average length of stay is directly supported by the abstract-level profile. However, the stronger statement that the spending increase was 'driven mainly' by longer stays requires a decomposition of the spending increase, and the supplied abstract profile explicitly does not provide that mechanism-level decomposition.

Study evidence

After private equity acquisition, average hospice length of stay increased relative to matched non‑PE for‑profit hospices.+6.3 days (relative to control)

“Using 100 percent fee-for-service Medicare claims, we compared 191 hospices newly acquired by private equity firms between 2018 and 2022 with 1,305 matched control hospices owned by for-profit but not private equity owners.”

Claim 2 of 5Not coveredThe researchers found no increase in services at private equity-acquired hospices, and instead fewer social work visits; there were no increases in physician, nurse, or home health visits that may have kept patients alive longer.View evidenceHide evidence

Why this verdict

The supplied abstract-level profile does not report visit-level service outcomes such as social work, physician, nurse, or home health visits. It therefore cannot verify the story’s claim that services did not increase, that social work visits fell, or that there were no increases in visit types that might explain longer survival/live discharge.

Study evidence

After private equity acquisition, average hospice length of stay increased relative to matched non‑PE for‑profit hospices.+6.3 days (relative to control)

“Using 100 percent fee-for-service Medicare claims, we compared 191 hospices newly acquired by private equity firms between 2018 and 2022 with 1,305 matched control hospices owned by for-profit but not private equity owners.”

Claim 3 of 5Not coveredThe findings are published in the November issue of Health Affairs.View evidenceHide evidence

Why this verdict

The supplied paper profile identifies the document and abstract-level scientific content but does not provide publication issue metadata confirming publication in the November issue of Health Affairs.

Claim 4 of 5SupportedA study of for-profit hospices acquired by private equity firms found that Medicare spending rose by 5.9 percent per hospice stay after acquisition, compared with similar for-profit hospices that weren't acquired.View evidenceHide evidence

As stated5.9 percent per hospice stay

Why this verdict

The abstract-level profile reports that Medicare spending increased by $993 per hospice encounter, approximately 5.9% of a $16,922 baseline, after private equity acquisition relative to matched for-profit non-private-equity controls. The story frames this as a study finding rather than as a proven causal mechanism, which is consistent with the difference-in-differences observational design.

Study evidence

After private equity acquisition, average hospice length of stay increased relative to matched non‑PE for‑profit hospices.+6.3 days (relative to control)

“Using 100 percent fee-for-service Medicare claims, we compared 191 hospices newly acquired by private equity firms between 2018 and 2022 with 1,305 matched control hospices owned by for-profit but not private equity owners.”

Claim 5 of 5SupportedThe article says the longer stays and live discharges were likely related to shifts toward patients who use less daily care, including a significant increase in the share of patients with dementia, consistent with a larger share of patients discharged from hospice alive.View evidenceHide evidence

Why this verdict

The profile supports the core interpretation: longer stays, increased live discharge, and increased dementia share are reported, and the authors interpret these patterns as consistent with selection of beneficiaries requiring less intense care under non-risk-adjusted per-diem hospice payment. The claim is hedged as likely/speculative rather than proven, broadly matching the paper’s tentative 'may help explain' framing.

Study evidence

After private equity acquisition, average hospice length of stay increased relative to matched non‑PE for‑profit hospices.+6.3 days (relative to control)

“Using 100 percent fee-for-service Medicare claims, we compared 191 hospices newly acquired by private equity firms between 2018 and 2022 with 1,305 matched control hospices owned by for-profit but not private equity owners.”

Study evidence

Observed increases in length-of-stay, live discharge rates, and the share of beneficiaries with dementia in private equity–owned hospices are presented as consistent with selection of beneficiaries requiring less intense care under Medicare’s non–risk-adjusted per-diem hospice payment.

“Selection of beneficiaries requiring less intense care-a profit-maximizing strategy under daily non-risk-adjusted capitated payments-may help explain these findings.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Private equity acquisition cohort consisted of 191 hospices acquired between 2018 and 2022, compared with 1,305 matched for-profit non-private-equity control hospices.
The presented story describes the comparison group but does not report the cohort sizes or acquisition-year window supplied in the paper profile.
From Difference-in-differences with matched control hospices
Policy implication that reforming hospice payment may mitigate patient selection incentives.
The supplied story presentation does not mention the paper’s payment-reform implication.
From Economic/behavioral interpretation
Limitation: difference-in-differences with matched controls may not eliminate residual confounding or differential trends.
The story mentions the comparison design but does not acknowledge the interpretation-changing limitation that observational quasi-experimental estimates can still be affected by residual confounding or nonparallel trends.
From Difference-in-differences with matched control hospices
Limitation: Medicare fee-for-service claims may not generalize to Medicare Advantage or non-Medicare populations and have limited clinical detail about severity, functional status, and reasons for discharge.
The story notes use of Medicare fee-for-service claims but does not report the resulting generalizability and clinical-detail limitations.
From Difference-in-differences with matched control hospices

6 things the story did carry across

Quasi-experimental difference-in-differences design using 100% Medicare fee-for-service claims and matched for-profit non-private-equity hospice controls.
Medicare spending per hospice encounter increased after private equity acquisition by $993, approximately 5.9% from baseline, relative to matched controls.
Average hospice length of stay increased by 6.3 days relative to matched controls after acquisition.
Beneficiaries at private-equity-acquired hospices were more likely to be discharged alive, and the share of beneficiaries with dementia increased.
Authors’ interpretive mechanism: observed patterns may reflect selection of beneficiaries requiring less intense care under non-risk-adjusted daily hospice payments.
Limitation: the proposed beneficiary-selection mechanism is interpretive and not independently tested in the abstract-level evidence.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEstimate how private equity acquisition of hospices affects hospice utilization patterns, patient mix, patient outcomes (including live discharge), and Medicare spending.Difference-in-differences with matched control hospicesExpand

In plain English

Quasi-experimental analysis using 100% fee-for-service Medicare claims compared 191 hospices acquired by private equity (2018–2022) to 1,305 matched for‑profit non‑PE control hospices in a difference‑in‑differences framework. After acquisition, beneficiaries in PE‑owned hospices had longer average hospice length of stay (+6.3 days relative to control), higher likelihood of live discharge, a larger share with dementia, and higher Medicare spending per hospice encounter (+$993, ≈5.9% of baseline $16,922). Authors propose beneficiary selection toward less‑intensive needs under non‑risk‑adjusted per‑diem payments as a possible mechanism.

Key findings

After private equity acquisition, average hospice length of stay increased relative to matched non‑PE for‑profit hospices.+6.3 days (relative to control)
Beneficiaries in PE‑owned hospices were more likely to be discharged alive after acquisition compared with controls.

“Using 100 percent fee-for-service Medicare claims, we compared 191 hospices newly acquired by private equity firms between 2018 and 2022 with 1,305 matched control hospices owned by for-profit but not private equity owners.”

What this piece can’t prove

Findings are based on Medicare fee‑for‑service administrative claims and may not generalize to Medicare Advantage or non‑Medicare populations.
Claims data limit clinical detail (severity, functional status) and reasons for discharge, which constrains interpretation of observed changes in outcomes and patient mix.
Difference‑in‑differences with matched controls reduces but may not eliminate residual confounding or differential trends between acquired and control hospices; the abstract does not present diagnostic checks or robustness analyses.
The abstract does not report statistical uncertainty (confidence intervals or p‑values) or detailed model covariates in the summary.

2otherProvide an economic/behavioral interpretation that observed changes are consistent with beneficiary selection under non–risk-adjusted per-diem hospice payments, motivating policy reform.Economic/behavioral interpretationExpand

In plain English

The authors interpret observed post-acquisition changes—longer average hospice length-of-stay, higher likelihood of live discharge, and an increased share of beneficiaries with dementia in private equity–owned hospices—as consistent with profit-motivated beneficiary selection under Medicare’s daily capitated (per-diem), non–risk-adjusted hospice payment. They argue this selection could raise Medicare spending per encounter and suggest reforming hospice payment to mitigate such selection.

Key findings

Observed increases in length-of-stay, live discharge rates, and the share of beneficiaries with dementia in private equity–owned hospices are presented as consistent with selection of beneficiaries requiring less intense care under Medicare’s non–risk-adjusted per-diem hospice payment.

“Selection of beneficiaries requiring less intense care-a profit-maximizing strategy under daily non-risk-adjusted capitated payments-may help explain these findings.”

What this piece can’t prove

Interpretive/policy argument is not an independent empirical test of the proposed selection mechanism.
Causal attribution of selection to per-diem, non–risk-adjusted payments is inferential and may be confounded by other simultaneous changes associated with private equity ownership.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer